Suppr超能文献

伴有转移的患者:IV 期葡萄膜黑色素瘤,一项国际研究。

Patients presenting with metastases: stage IV uveal melanoma, an international study.

机构信息

Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA.

Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA

出版信息

Br J Ophthalmol. 2022 Apr;106(4):510-517. doi: 10.1136/bjophthalmol-2020-317949. Epub 2021 Jan 15.

Abstract

OBJECTIVE

To analyse ocular and systemic findings of patients presenting with systemic metastasis.

METHODS AND ANALYSIS

It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011. Data included: primary tumour dimensions, extrascleral extension, ciliary body involvement, American Joint Committee on Cancer (AJCC)-tumour, node, metastasis staging, characteristics of metastases.

RESULTS

Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV). These melanomas originated in the iris, ciliary body and choroid in 4%, 16% and 80% of eyes, respectively. Using eighth edition AJCC, 8 (11%), 20 (29%), 24 (35%), and 17 (25%) belonged to AJCC T-categories T1-T4. Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4). Regional lymph node metastases (N1a) were detected in 9 (13%) patients of whom 6 (67%) had extrascleral extension. Stage of systemic metastases (known for 40 (59%) stage IV patients) revealed 14 (35%), 25 (63%) and 1 (2%) had small (M1a), medium-sized (M1b) and large-sized (M1c) metastases, respectively. Location of metastases in stage IV patients were liver (91%), lung (16%), bone (9%), brain (6%), subcutaneous tissue (4%) and others (5%). Multiple sites of metastases were noted in 24%. Compared with the 98.1% of patients who did not present with metastases, those with synchronous metastases had larger intraocular tumours, more frequent extrascleral extension, ciliary body involvement and thus a higher AJCC T-category.

CONCLUSIONS

Though higher AJCC T-stage was associated with risk for metastases at diagnosis, even small T1 tumours were stage IV at initial presentation. The liver was the most common site of metastases; however, frequent multiorgan involvement supports initial whole-body staging.

摘要

目的

分析出现全身转移的患者的眼部和全身表现。

方法和分析

这是一项国际性的、多中心的、基于互联网的、基于登记的回顾性数据分析。患者于 2001 年至 2011 年期间被诊断。数据包括:原发肿瘤的大小、眼外扩展、睫状体受累、美国癌症联合委员会(AJCC)-肿瘤、淋巴结、转移分期、转移特征。

结果

在 3610 例葡萄膜黑色素瘤患者中,有 69 例(1.9%;95%CI 1.5 至 2.4)出现临床转移(IV 期)。这些黑色素瘤起源于虹膜、睫状体和脉络膜的比例分别为 4%、16%和 80%。使用第八版 AJCC,8 例(11%)、20 例(29%)、24 例(35%)和 17 例(25%)属于 AJCC T 分期 T1-T4。同步转移的风险从 T1 的 0.7%增加到 T2 的 1.5%、T3 的 2.6%和 T4 的 7.9%。9 例(13%)患者出现区域淋巴结转移(N1a),其中 6 例(67%)有眼外扩展。全身转移分期(已知 40 例(59%)IV 期患者的分期)显示,14 例(35%)、25 例(63%)和 1 例(2%)分别为小(M1a)、中(M1b)和大(M1c)转移。IV 期患者的转移部位为肝脏(91%)、肺(16%)、骨(9%)、脑(6%)、皮下组织(4%)和其他部位(5%)。24%的患者有多个部位的转移。与 98.1%无转移的患者相比,有同步转移的患者眼内肿瘤更大,更频繁地出现眼外扩展、睫状体受累,因此 AJCC T 分期更高。

结论

尽管较高的 AJCC T 分期与诊断时转移的风险相关,但即使是小的 T1 肿瘤在初次就诊时也是 IV 期。肝脏是转移最常见的部位;然而,频繁的多器官受累支持初始全身分期。

相似文献

1
Patients presenting with metastases: stage IV uveal melanoma, an international study.
Br J Ophthalmol. 2022 Apr;106(4):510-517. doi: 10.1136/bjophthalmol-2020-317949. Epub 2021 Jan 15.
2
International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma.
JAMA Ophthalmol. 2015 Apr;133(4):376-83. doi: 10.1001/jamaophthalmol.2014.5395.
3
American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients.
Ophthalmology. 2013 Oct;120(10):2066-71. doi: 10.1016/j.ophtha.2013.03.012. Epub 2013 May 9.
4
Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
Ophthalmology. 2018 Jun;125(6):913-923. doi: 10.1016/j.ophtha.2017.11.040. Epub 2018 Jan 17.
5
Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan.
Turk Patoloji Derg. 2016;32(3):186-92. doi: 10.5146/tjpath.2015.01357.
6
Posterior uveal melanoma in 321 Asian Indian patients: analysis based on the 8th edition of American Joint Committee Cancer classification.
Int Ophthalmol. 2020 Nov;40(11):3087-3096. doi: 10.1007/s10792-020-01494-2. Epub 2020 Jun 29.
10
[Local, regional and systemic dissemination of choroidal melanoma : Clinical and pathological correlation from 2 cases].
J Fr Ophtalmol. 2019 Oct;42(8):834-838. doi: 10.1016/j.jfo.2019.05.004. Epub 2019 Jun 10.

引用本文的文献

1
Survival outcomes and prognosis predictors of uveal melanoma from Indian population.
Indian J Ophthalmol. 2025 Aug 1;73(8):1138-1145. doi: 10.4103/IJO.IJO_350_25. Epub 2025 Jul 28.
2
Precision prognostic model for uveal melanoma: nomogram prediction and comparison with AJCC system.
Discov Oncol. 2025 Jul 18;16(1):1369. doi: 10.1007/s12672-025-03212-9.
4
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.
Acta Derm Venereol. 2024 Dec 12;104:adv41297. doi: 10.2340/actadv.v104.41297.
5
Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021.
Ther Adv Med Oncol. 2024 Aug 23;16:17588359241273020. doi: 10.1177/17588359241273020. eCollection 2024.
6
Association Between Uveal Melanoma and Allostatic Load.
Anticancer Res. 2024 Aug;44(8):3375-3380. doi: 10.21873/anticanres.17158.
8
Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment.
Oncologist. 2024 Aug 5;29(8):e1098-e1099. doi: 10.1093/oncolo/oyae112.
9
Pathological and Molecular Diagnosis of Uveal Melanoma.
Diagnostics (Basel). 2024 May 2;14(9):958. doi: 10.3390/diagnostics14090958.
10
The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.
Ophthalmol Ther. 2024 May;13(5):1103-1123. doi: 10.1007/s40123-024-00913-2. Epub 2024 Mar 18.

本文引用的文献

1
5
Ipsilateral metastatic choroidal melanoma responds to systemic immunotherapy.
Eur J Ophthalmol. 2020 Sep;30(5):NP69-NP73. doi: 10.1177/1120672119839925. Epub 2019 Apr 4.
6
Clinical predictors of survival in metastatic uveal melanoma.
Jpn J Ophthalmol. 2019 Mar;63(2):197-209. doi: 10.1007/s10384-019-00656-9. Epub 2019 Feb 22.
7
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.
Melanoma Res. 2019 Dec;29(6):561-568. doi: 10.1097/CMR.0000000000000575.
8
Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma.
Cancer Res Treat. 2018 Oct;50(4):1130-1139. doi: 10.4143/crt.2017.171. Epub 2017 Dec 4.
10
Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group.
Am J Ophthalmol. 2016 Aug;168:217-226. doi: 10.1016/j.ajo.2016.06.002. Epub 2016 Jun 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验